Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflict of interest. 16. Int J Cancer. 2024 Jan 15;154(2):226-240. doi: 10.1002/ijc.34694. Epub 2023 Aug 19. Twenty-year outcome of prevalence, incidence, mortality and survival rate in patients with malignant bone tumors. Xu Y(1)(2)(3), Shi F(1)(2)(3)(4), Zhang Y(1)(2)(3), Yin M(1)(2)(3)(5), Han X(1)(2)(3), Feng J(1)(2)(3), Wang G(1)(2)(3). Author information: (1)Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China. (2)Tianjin's Clinical Research Center for Cancer, Tianjin, China. (3)Key Laboratory of Cancer Prevention and Therapy, Tianjin, China. (4)Department of Spinal Surgery, The Affiliated Hospital of Chengde Medical University, Chengde, Hebei, China. (5)Department of Orthopedics, The Fifth Central Hospital of Tianjin, Tianjin, China. Malignant bone tumors are a group of rare malignant tumors and our study aimed to update the recent epidemiologic estimates based on the Surveillance, Epidemiology and End Results database. Patients diagnosed with malignant bone tumors from 2000 to 2019 were included and their characteristics were retrospectively described. The limited-duration prevalence, annual age-adjusted incidence and mortality were calculated, and the annual percentage changes were analyzed to quantify the rate change. Finally, observed survival and relative survival rate were illustrated. Subgroup analysis across tumor type, age, gender, tumor Grade, primary tumor site and stage was also performed. As for results, a total of 11 655 eligible patients with malignant bone tumor were selected. Osteosarcoma was the most common tumor type, followed by chondrosarcoma, Ewing sarcoma and chordoma. The estimated limited-duration prevalence of malignant bone tumors increased from 2000 (0.00069%) to 2018 (0.00749%). Steady age-adjusted incidence was observed in all patients during the study period while the highest rate occurred in osteosarcoma. Mortality rates differed in subgroups while elder patients (older than 64 years) presented the highest mortality rate compared to other age groups. In all bone tumors, the 10-year observed survival and relative survival rates were 58.0% and 61.9%, respectively. Chondrosarcoma patients had the best survival outcome, followed by osteosarcoma, Ewing sarcoma, chordoma and other bone tumors. In conclusion, different epidemiologic performance in incidence and mortality was observed across tumor type as well as other demographic and clinicopathological variables, which provide potential suggestion for further adjustment of medical resource. © 2023 UICC. DOI: 10.1002/ijc.34694